NASDAQ:QTTB Q32 Bio (QTTB) Stock Price, News & Analysis $42.82 -2.99 (-6.53%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$40.66▼$47.3850-Day Range$17.33▼$45.8152-Week Range$8.24▼$47.38Volume152,753 shsAverage Volume59,217 shsMarket Capitalization$511.36 millionP/E RatioN/ADividend YieldN/APrice Target$62.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Q32 Bio alerts: Email Address Q32 Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.20 Rating ScoreUpside/Downside45.4% Upside$62.25 Price TargetShort InterestBearish7.38% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.25Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($11.76) to ($4.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.57 out of 5 starsMedical Sector638th out of 910 stocksPharmaceutical Preparations Industry291st out of 426 stocks 3.6 Analyst's Opinion Consensus RatingQ32 Bio has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageQ32 Bio has only been the subject of 1 research reports in the past 90 days.Read more about Q32 Bio's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.38% of the float of Q32 Bio has been sold short.Short Interest Ratio / Days to CoverQ32 Bio has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Q32 Bio has recently increased by 13.69%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldQ32 Bio does not currently pay a dividend.Dividend GrowthQ32 Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for QTTB. Previous Next 1.8 News and Social Media Coverage News SentimentQ32 Bio has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Q32 Bio this week, compared to 1 article on an average week.MarketBeat FollowsOnly 2 people have added Q32 Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Q32 Bio insiders have not sold or bought any company stock.Percentage Held by Insiders16.10% of the stock of Q32 Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.32% of the stock of Q32 Bio is held by institutions.Read more about Q32 Bio's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Q32 Bio are expected to grow in the coming year, from ($11.76) to ($4.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Q32 Bio is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Q32 Bio is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQ32 Bio has a P/B Ratio of 15.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Q32 Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Deal MakerThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.Learn more about this much-needed advancement and investment opportunity here. About Q32 Bio Stock (NASDAQ:QTTB)Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.Read More QTTB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QTTB Stock News HeadlinesSeptember 7 at 6:42 AM | americanbankingnews.comQ32 Bio (NASDAQ:QTTB) Reaches New 12-Month High at $45.00September 1, 2024 | americanbankingnews.comQ32 Bio (NASDAQ:QTTB) Reaches New 12-Month High at $43.48September 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 29, 2024 | seekingalpha.comQ32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097August 29, 2024 | prnewswire.comQ32 Bio to Participate in Upcoming September Investor ConferencesAugust 23, 2024 | markets.businessinsider.comPiper Sandler Sticks to Their Buy Rating for Q32 Bio (QTTB)August 19, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Edwards Lifesciences (EW), Immunovant (IMVT) and Q32 Bio (QTTB)August 10, 2024 | morningstar.comQ32 Bio Inc QTTBSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 8, 2024 | investorplace.comQTTB Stock Earnings: Q32 Bio Misses EPS for Q2 2024August 8, 2024 | finanznachrichten.deQ32 Bio Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateJuly 27, 2024 | markets.businessinsider.comBuy Rating on Q32 Bio: Promising Clinical Trials and Market Potential for BempikibartJuly 23, 2024 | nasdaq.comQ32 Bio Rings the Closing BellJuly 23, 2024 | seekingalpha.comQTTB Q32 Bio Inc.July 9, 2024 | prnewswire.comQ32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic DermatitisJuly 1, 2024 | prnewswire.comQ32 Bio Joins Russell 3000® IndexMay 22, 2024 | msn.comLeerink Partners Initiates Coverage of Q32 Bio (QTTB) with Outperform RecommendationMay 21, 2024 | markets.businessinsider.comBuy Rating Justified by Q32 Bio’s Promising Pipeline and Market PotentialSee More Headlines Receive QTTB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Q32 Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:QTTB Previous SymbolNASDAQ:QTTB CUSIPN/A CIK1661998 Webwww.homologymedicines.com Phone781-301-7277FaxN/AEmployees39Year FoundedN/APrice Target and Rating Average Stock Price Target$62.25 High Stock Price Target$100.00 Low Stock Price Target$45.00 Potential Upside/Downside+45.4%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($32.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,960,000.00 Net MarginsN/A Pretax Margin-22,326.84% Return on Equity-129.44% Return on Assets-62.88% Debt Debt-to-Equity Ratio0.37 Current Ratio6.49 Quick Ratio6.49 Sales & Book Value Annual Sales$-6,651,000.00 Price / Sales-76.88 Cash FlowN/A Price / Cash FlowN/A Book Value$2.78 per share Price / Book15.40Miscellaneous Outstanding Shares11,942,000Free Float10,019,000Market Cap$511.36 million OptionableN/A Beta-0.32 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMs. Jodie Pope Morrison (Age 48)CEO & Director Comp: $852.63kDr. Shelia M. Violette Ph.D. (Age 63)Co-founder, Chief Scientific Officer & President of Research Comp: $619.93kDr. Jason A. Campagna M.D. (Age 57)Ph.D., Chief Medical Officer Comp: $680.93kMr. Lee H. Kalowski M.B.A. (Age 43)CFO, President & Treasurer Dr. Saul Fink Ph.D.Chief Technology OfficerMr. David Appugliese J.D.Senior VP & Head of PeopleMs. Maria Marzilli M.P.H.Executive Vice President of Corporate Strategy & Program OperationsMs. Kathryn E. Golden M.B.A.Head of Chemistry, Manufacturing & ControlsMore ExecutivesKey CompetitorsMirum PharmaceuticalsNASDAQ:MIRMKeros TherapeuticsNASDAQ:KROSZai LabNASDAQ:ZLABGalapagosNASDAQ:GLPGKiniksa PharmaceuticalsNASDAQ:KNSAView All CompetitorsInsiders & InstitutionsEnsign Peak Advisors IncBought 38,750 shares on 8/13/2024Ownership: 0.540%Harvard Management Co. Inc.Bought 162,965 shares on 8/9/2024Ownership: 1.365%Renaissance Technologies LLCBought 14,764 shares on 8/9/2024Ownership: 0.124%Rhumbline AdvisersBought 7,593 shares on 8/1/2024Ownership: 0.064%Bank of New York Mellon CorpBought 17,569 shares on 7/26/2024Ownership: 0.147%View All Insider TransactionsView All Institutional Transactions QTTB Stock Analysis - Frequently Asked Questions How have QTTB shares performed this year? Q32 Bio's stock was trading at $17.04 at the start of the year. Since then, QTTB shares have increased by 151.3% and is now trading at $42.82. View the best growth stocks for 2024 here. How were Q32 Bio's earnings last quarter? Q32 Bio Inc. (NASDAQ:QTTB) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($1.00) by $0.42. Who are Q32 Bio's major shareholders? Top institutional shareholders of Q32 Bio include Harvard Management Co. Inc. (1.36%), Ensign Peak Advisors Inc (0.54%), Bank of New York Mellon Corp (0.15%) and Renaissance Technologies LLC (0.12%). View institutional ownership trends. How do I buy shares of Q32 Bio? Shares of QTTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:QTTB) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q32 Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Q32 Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
